PowerPoint 3

Vision
Chapter 1. Chapter 2. Chapter 3.
Appendix
- ‘POP Biotech’ ‘EuPOP’
•


• CRMO
- EuVCTTM ( )
- EuIMTTM ( )

3)

1)
2)
20 12 11 1/2 21 1 20 IND
Chapter 1.
2. -19_
6
-19 : 100 (5 364)
• 1 : 19~50 50 , ,
• 2 : 4 19~75 230 ,
• 3 :
-19
EuIMT () +
DNA mRNA

(DNA, RNA) ()


, DNA
RNA
•
• mRNA
• , • (2~8)
• •
•
• • 65 ↓ •

• ‘’
•
•
•

• (66%) / 1 • (91%)
• •
- ‘SK’
- ‘’
,
10 or 20 µg ( 100 µg / 30 µg )
2~8 (mRNA )
-19
, ,
/ ( GMP )
19 ,
-19



(421 )
(), SBH()

CMO & GMP CRMO CRMO
2 ‘V’ Plant
3) SNAP : Spontaneous Nanoliposome Antigen Particleization ( POP Bio Nano Particle)


11
→ (CRM197)

* EuVCTTM : EuBiologics Vaccine Conjugation Technology
CPS CPS-ADH
EuVCTTM
1) : KIST 2017.11.13
2) ( ) :
* MPL (TLR4 agonist)
* TLR (Toll like receptor / Toll )
TLR ,


MPL(TLR4 agonist)

2) MPL
3)
1) 30
2)
→ /
GLA (Glucopyranosyl Lipid A)
GSK Shingrix ( ) 17.10 18 1.2 19 2.7
GSK MPL
GLA EcML
14
EcML
(Nature)
SNAP 19 (Advanced Materials)

-(PoP)
Tag

SNAP ( )
• Jonathan Lovell 2016
•
Chapter 3.
EuVCT
EuIMT
ATGC 100
1/2
3
3
3
1

3 WHO-PQ


Chapter 3.
/
EuVCT 3
Chapter 3.
(RSV)
, 5 , 1~3
99% 99% /
2 300 , 16 . 1
2006
GSK Shingrix


. 10 1 ,
(HZV)
18 20
22 24

- -19


1 (‘C’ Plant) 56, 2 (‘V’ Plant) 1100
174.3 (20 12 31 )
227 (20 12 31 )

2. CRMO


• • • CJ QA • •
• • • CJ • LG •
Company Profile
85.22%

2 : TCV, PCV, MCV,
4 :
- 3,000L
( , )
-


(VexPert) 2018.08.21 300 (19.2%) - ( / )
(Fium Bio) 2019.07.24 450 (21.4%) - HA /
(ATGC) 2019.01.10 2,100 (2.9%) - /
CMO
(Plumline) 2019.08.08 450 (1.7%) - -
(G Biologics) 2020.08.21 1,000 (4.4%) - -
(Eyegene) ’18~’20 2 30
- / -
~’21 2,000 (2.78%) -
POP Biotech ~’20/’21 $ 300 (25%) -
Eupop Life Science (JV) ~’20/’21 $ 125 (62.5%) -
(RSV, , )
27,645 21,497
40,593 71,268
33,073
13,164
19,909
10,099
9,809
545
361
1,186
11,785